Ionis Pharmaceuticals IONS Early Repayment Of Convertible Debt
Discontinued — last reported Q4 '25
Early Repayment Of Convertible Debt at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:EarlyRepaymentOfConvertibleDebt.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's early repayment of convertible debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's early repayment of convertible debt?
- Ionis Pharmaceuticals (IONS) reported early repayment of convertible debt of $66.91M in Q4 2025.
- What is the long-term trend for Ionis Pharmaceuticals's early repayment of convertible debt?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's early repayment of convertible debt has grown at a 1.0% compound annual growth rate (CAGR), from $256.96M to $267.64M.
- What does early repayment of convertible debt mean?
- Cash used to pay off convertible debt early.
- How do you interpret early repayment of convertible debt?
- Repayment reduces future interest burdens and potential dilution, signaling a strong cash position or a desire to clean up the balance sheet.
- How does early repayment of convertible debt compare across companies?
- Common in companies with complex capital structures and convertible notes.